Vascular biology of eicosanoids and atherogenesis

@article{Pratic2009VascularBO,
  title={Vascular biology of eicosanoids and atherogenesis},
  author={Domenico Pratic{\`o} and Jean Michel Dogn{\'e}},
  journal={Expert Review of Cardiovascular Therapy},
  year={2009},
  volume={7},
  pages={1079 - 1089}
}
Atherosclerosis is a chronic and progressive inflammatory vascular disease that is characterized by a complex interplay between some components of the bloodstream and the arterial wall. The lipid derivatives eicosanoids have been identified as important mediators that contribute to mechanisms of atherogenesis. Prostaglandins and thromboxane A2 are members of the eicosanoid family synthesized from arachidonic acid by the combined action of cyclooxygenases and prostaglandins and thromboxane A2… 
Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke
TLDR
This intricate network of lipid mediators is unique considering that from a single precursor, arachidonic acid, may derive an array of bioproducts that interact within each other synergizing or, more often, behaving as functional antagonists.
Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
TLDR
The history, biology and cardiovascular function of key eicosanoids with particular focus on prostacyclin and other COX products are summarized and how knowledge of these pathways can applied in future drug discovery and be used to explain the cardiovascular side‐effects of NSAIDs are discussed.
The roles of cytochromes P 450 in vascular biology and cardiovascular homeostasis
Cardiovascular disease and atherosclerosis are human health crises that remain the leading cause of death worldwide. The cytochromes P450 (CYPs) are key metabolizing enzymes of both xenobiotics and
Prostaglandins and Other Lipid Mediators ould the thromboxane A 2 pathway be a therapeutic target for the reatment of OSA-induced atherosclerosis ?
Obstructive sleep apnea (OSA) is characterized by recurrent nocturnal episodes of intermittent hypoxia. This disease is associated with premature atherosclerosis and consequently with increased
Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease
TLDR
Considering the importance of these multiple and not necessarily inflammatory mechanisms may help to delineate the exact nature of the involvement of the brain COXs and 5-LOX in AD and would reinvigorate the search for novel targets for AD therapy.
Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.
TLDR
Evaluating the effect of the TP receptor antagonist and thromboxane synthase inhibitor EV-077 on inflammatory markers in human umbilical vein endothelial cells and on human coronary artery smooth muscle cell proliferation suggested that the throm boxane pathway may be associated with early atherosclerosis in terms of endothelial dysfunction and vascular hypertrophy.
When endothelial progenitor cell says I2 shall limit neointima formation!
  • J. Sainz, M. Sata
  • Medicine, Biology
    Arteriosclerosis, thrombosis, and vascular biology
  • 2010
TLDR
It is reported that prostaglandin I2(PGI2) improves EPC function via a PGI2 receptor, which is termed IP receptor, in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology.
Eicosanoids and HB-EGF/EGFR in cancer
TLDR
The contribution of HB-EGF, an important EGFR ligand, to the cardiac dysfunction related to decreased shedding of HB -EGF after COX-2/PGE2 inhibition is delineated.
Phospholipid Remodeling in Physiology and Disease.
TLDR
Mounting evidence suggests that changes in LPCAT activity may be potentially involved in pathological conditions, including nonalcoholic fatty liver disease, atherosclerosis, viral infections, and cancer, and Pharmacological manipulation of L PCAT activity and membrane phospholipid composition may provide new therapeutic options for these conditions.
Could the thromboxane A2 pathway be a therapeutic target for the treatment of obstructive sleep apnea-induced atherosclerosis?
TLDR
The recent findings on the intricate interaction between the TXA2-pathway, chronic intermittent hypoxia and atherosclerosis are reviewed and promising therapeutic strategies to treat OSA-related atherogenesis are suggested, including pharmacological and/or nutritional approaches.
...
1
2
3
4
...

References

SHOWING 1-10 OF 106 REFERENCES
New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
TLDR
This review will propose a description of the recently described thromboxane modulators of major interest, which combine another pharmacological activity such as, platelet activating factor antagonism, angiotensin II antagonism or 5-lipoxygenase inhibition.
Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis.
TLDR
It is demonstrated that thromboxane as well as prostacyclin biosynthesis is increased in 2 murine models of atherogenesis and is secondary to increased in vivo platelet activation.
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.
TLDR
This review highlights recent breakthroughs in the roles of F2-IPs, TxA2 and PGI2 in atherogenesis, and identifies pertinent therapeutic targets for managing atherosclerosis.
The isoprostanes in biology and medicine
TLDR
Consistent data suggest that formation of F2-isoprostanes is altered in a variety of clinical settings putatively associated with oxidant stress, suggesting that they may also act as mediators of the cellular effects of oxidative stress.
Involvement of Thromboxane Receptor in the Proatherogenic Effect of Isoprostane F2&agr;-III: Evidence From Apolipoprotein E– and LDL Receptor–Deficient Mice
TLDR
The results demonstrate that in atherosclerosis iPF2&agr;-III is not only a biomarker of oxidative stress but also an active mediator of its vascular phenotype, and suppression of the first alone would not provide the most benefit for patients because the coincidental presence of the isoprostane will still have a proatherogenic effect.
New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators.
TLDR
This review focuses on the latest chemical and pharmacological developments in the field of the prostacyclin agonists, which have been synthesized and pharmacologically evaluated.
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
TLDR
Comparisons of the effects of aspirin and the TP receptor antagonist S18886 suggest that blockade of TP receptors inhibits atherosclerosis by a mechanism independent of platelet-derived TxA(2), perhaps by preventing the expression of adhesion molecules whose expression is stimulated by eicosanoids other than Tx a(2).
A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
TLDR
Results show for the first time that this dual Tx inhibitor is effective in reducing atherogenesis in the LDL receptor deficient mice, and demonstrate the novel concept that this therapeutic approach halts the progression of the disease and influences the cellular composition of the atherosclerotic plaques.
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
TLDR
Evidence that COX-1-derived prostanoids contribute to atherogenesis suggests that controlled evaluation of the effects of nonsteroidal anti-inflammatory drugs and/or aspirin on plaque progression in humans is timely.
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
TLDR
In an animal model of acute inflammation, a selective inhibitor of COX-2 inhibited edema at the inflammatory site and was analgesic but had no effect on PG production in the stomach and did not cause gastric toxicity.
...
1
2
3
4
5
...